KR20240022544A - 신경 작용제-유도 발작을 치료하는 방법 - Google Patents
신경 작용제-유도 발작을 치료하는 방법 Download PDFInfo
- Publication number
- KR20240022544A KR20240022544A KR1020247000572A KR20247000572A KR20240022544A KR 20240022544 A KR20240022544 A KR 20240022544A KR 1020247000572 A KR1020247000572 A KR 1020247000572A KR 20247000572 A KR20247000572 A KR 20247000572A KR 20240022544 A KR20240022544 A KR 20240022544A
- Authority
- KR
- South Korea
- Prior art keywords
- tezampanel
- benzodiazepine
- hours
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208885P | 2021-06-09 | 2021-06-09 | |
| US63/208,885 | 2021-06-09 | ||
| PCT/US2022/032783 WO2022261287A1 (en) | 2021-06-09 | 2022-06-09 | Methods of treating nerve agent-induced seizures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240022544A true KR20240022544A (ko) | 2024-02-20 |
Family
ID=84425551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247000572A Pending KR20240022544A (ko) | 2021-06-09 | 2022-06-09 | 신경 작용제-유도 발작을 치료하는 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277696A1 (https=) |
| EP (1) | EP4352047A4 (https=) |
| JP (1) | JP2024521430A (https=) |
| KR (1) | KR20240022544A (https=) |
| CN (1) | CN117836284A (https=) |
| AU (1) | AU2022291138A1 (https=) |
| CA (1) | CA3222575A1 (https=) |
| IL (1) | IL309097A (https=) |
| MX (1) | MX2023014418A (https=) |
| WO (1) | WO2022261287A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1511741B1 (en) * | 2002-04-26 | 2012-12-26 | Eli Lilly And Company | Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics |
| US11045462B2 (en) * | 2016-06-14 | 2021-06-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods for treating neurological conditions and exposure to nerve agents |
| WO2018169798A1 (en) * | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
-
2022
- 2022-06-09 KR KR1020247000572A patent/KR20240022544A/ko active Pending
- 2022-06-09 CN CN202280052288.XA patent/CN117836284A/zh active Pending
- 2022-06-09 US US18/566,735 patent/US20240277696A1/en active Pending
- 2022-06-09 MX MX2023014418A patent/MX2023014418A/es unknown
- 2022-06-09 IL IL309097A patent/IL309097A/en unknown
- 2022-06-09 JP JP2023575935A patent/JP2024521430A/ja active Pending
- 2022-06-09 EP EP22821009.2A patent/EP4352047A4/en active Pending
- 2022-06-09 AU AU2022291138A patent/AU2022291138A1/en active Pending
- 2022-06-09 CA CA3222575A patent/CA3222575A1/en active Pending
- 2022-06-09 WO PCT/US2022/032783 patent/WO2022261287A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL309097A (en) | 2024-02-01 |
| WO2022261287A1 (en) | 2022-12-15 |
| JP2024521430A (ja) | 2024-05-31 |
| MX2023014418A (es) | 2024-02-13 |
| CN117836284A (zh) | 2024-04-05 |
| EP4352047A4 (en) | 2025-04-16 |
| EP4352047A1 (en) | 2024-04-17 |
| US20240277696A1 (en) | 2024-08-22 |
| AU2022291138A1 (en) | 2023-12-07 |
| CA3222575A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021229240B2 (en) | Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia | |
| CN102762201A (zh) | 注意力缺陷/多动症的治疗方法 | |
| KR20180023992A (ko) | 사회성 장애 및 물질 사용 장애의 치료를 위한 치료 화합물 및 조성물 | |
| BRPI0919241B1 (pt) | Processo para fabricação de compostos de quinolona, e composição compreendendo composto de quinolona | |
| AU2018309372B2 (en) | Methods of treating behavior alterations | |
| US20260076950A1 (en) | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome | |
| CN113698345B (zh) | 作为钾通道调节剂的化合物及其制备和应用 | |
| US20250099445A1 (en) | Methods of treatment of tuberous sclerosis complex | |
| JP2019504016A (ja) | アルキルジヒドロキノリンスルホンアミド化合物 | |
| KR20240022544A (ko) | 신경 작용제-유도 발작을 치료하는 방법 | |
| EP3353163B1 (en) | 2,3,4,5-tetrahydropyridin-6-amine derivatives | |
| KR102325568B1 (ko) | 오토탁신 또는 리소포스파티드산에 의해 유도된 암세포 침윤을 억제하는 항암용 약학적 조성물 | |
| US12544364B2 (en) | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome | |
| JP3681770B2 (ja) | 老年性痴呆症又はアルツハイマー病治療剤 | |
| WO2024220489A1 (en) | Deuterium-enriched compound for use in a method of treatment of multiple myeloma | |
| HK40058596A (zh) | 作为钾通道调节剂的化合物及其制备和应用 | |
| HK40058596B (en) | Compounds as potassium channel regulators and preparation and use thereof | |
| JP2024521959A (ja) | オピエート離脱又はオピエート再発に関連する状態を治療又は予防する方法 | |
| OA21483A (en) | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome. | |
| TW202124359A (zh) | 用於增加磷酸化ampk蛋白含量之方法及材料 | |
| NZ732033B2 (en) | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia | |
| HK1248223A1 (en) | Solid forms of a compound modulating kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20240105 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250605 Comment text: Request for Examination of Application |